Phage display is a way to find peptides that bind a chosen target. Researchers attach large numbers of peptide variants to the surface of bacteriophages, viruses that infect bacteria, pull out the ones that stick, and read their sequences from the phage DNA. George Smith and Gregory Winter shared half of the 2018 Nobel Prize in Chemistry for developing phage display of peptides and antibodies.
Coverage here tracks new library designs. A 2026 study in the journal Pharmaceuticals built a library from about 482 venom-derived peptide scaffolds, used machine learning to pick which positions could be mutated, and found strong binders for all four targets tested: CD47, DLL3, IL33, and P2X7R. In October 2026, Texas A&M chemists reported in Nature Communications a phage-compatible way to close library peptides into two rings, which yielded bicyclic binders to the immune checkpoint protein PD-1.
See #bicyclic-peptide, #cyclic-peptide, and #venom-peptides.
A review from the Indian Institute of Technology Ropar, published October 4, 2026 in the Journal of Peptide Science, surveys linear and cyclic peptides that bind glypican-3, a cell-surface protein that is common in hepatocellular carcinoma but largely absent from normal adult liver. The peptides, found mainly through phage display and structure-guided design, have enabled PET, SPECT, and fluorescence imaging of liver tumors in preclinical models, and albumin-binding changes and cyclization have improved tumor-to-liver contrast and stability. The authors argue that small peptides penetrate tumors faster and clear more quickly than the antibodies used against the same target; the imaging work they review is preclinical.
Researchers led by Wenshe Ray Liu at Texas A&M University described in Nature Communications on Saturday, October 3, 2026 a method called PReP-Bicyc that closes phage-displayed peptides into two rings with a designed linker, which reacts first with a cysteine at the peptide's start and then with two internal cysteines, under mild conditions that keep the phages viable. Screening a library made this way against the immune checkpoint protein PD-1 produced bicyclic peptides with binding affinities below 1 micromolar (best about 400 nM) that selectively labeled PD-1-expressing cells and blocked the PD-1/PD-L1 interaction. The reported results come from laboratory experiments.
A venom-peptide discovery system published in Pharmaceuticals (MDPI) in 2026 paired phage display with a machine-learning model that predicts mutation-tolerant residues, building a library from roughly 482 venom-derived scaffolds. Screened against CD47, DLL3, IL33, and P2X7R, the resulting VCX library yielded strong binders for all four targets. Venom peptides are stabilized by multiple disulfide bonds and naturally evolved to hit GPCRs and ion channels, giving them structural stability that conventional peptides often lack.
A new phage display platform using ~482 venom-derived peptide scaffolds and machine learning-guided mutation design achieved a 100% success rate identifying strong binders across four diverse therapeutic targets (CD47, DLL3, IL33, P2X7R). The approach could accelerate venom peptide drug discovery for cancer, inflammation, and pain.